Pediatric antifungal therapy. Part II: Neonatal infections

U. D. Allen; S. Richardson; W. McGuire; E. Bow; J. Robinson; C. Rotstein; J. Doyle; D. Davies; C. Hui; N. Le Saux; P. Merchant; M. Laverdiere; S. Read

Pediatric antifungal therapy. Part II: Neonatal infections

U. D. Allen, S. Richardson, W. McGuire, E. Bow, J. Robinson, C. Rotstein, J. Doyle, D. Davies, C. Hui, N. Le Saux, P. Merchant, M. Laverdiere, S. Read

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

Original language	English (US)
Pages (from-to)	71-78
Number of pages	8
Journal	Minerva Pediatrica
Volume	62
Issue number	1
State	Published - Feb 2010
Externally published	Yes

Keywords

Antifungal agents
Candidiasis
Infant, newborn
Mycoses

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Cite this

@article{351263e6d58b4686be4864a0963f34ff,

title = "Pediatric antifungal therapy. Part II: Neonatal infections",

abstract = "The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.",

keywords = "Antifungal agents, Candidiasis, Infant, newborn, Mycoses",

author = "Allen, {U. D.} and S. Richardson and W. McGuire and E. Bow and J. Robinson and C. Rotstein and J. Doyle and D. Davies and C. Hui and {Le Saux}, N. and P. Merchant and M. Laverdiere and S. Read",

year = "2010",

month = feb,

language = "English (US)",

volume = "62",

pages = "71--78",

journal = "Minerva Pediatrica",

issn = "0026-4946",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "1",

}

TY - JOUR

T1 - Pediatric antifungal therapy. Part II

T2 - Neonatal infections

AU - Allen, U. D.

AU - Richardson, S.

AU - McGuire, W.

AU - Bow, E.

AU - Robinson, J.

AU - Rotstein, C.

AU - Doyle, J.

AU - Davies, D.

AU - Hui, C.

AU - Le Saux, N.

AU - Merchant, P.

AU - Laverdiere, M.

AU - Read, S.

PY - 2010/2

Y1 - 2010/2

N2 - The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

AB - The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

KW - Antifungal agents

KW - Candidiasis

KW - Infant, newborn

KW - Mycoses

UR - http://www.scopus.com/inward/record.url?scp=77952765620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952765620&partnerID=8YFLogxK

M3 - Article

C2 - 20212400

AN - SCOPUS:77952765620

SN - 0026-4946

VL - 62

SP - 71

EP - 78

JO - Minerva Pediatrica

JF - Minerva Pediatrica

IS - 1

ER -

Pediatric antifungal therapy. Part II: Neonatal infections

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this